Glioma

• 

  Subject Areas on Research

  • (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. 
  • 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. 
  • 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. 
  • 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. 
  • A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. 
  • A comprehensive outlook on intracerebral therapy of malignant gliomas. 
  • A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? 
  • A genetically tractable model of human glioma formation. 
  • A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. 
  • A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. 
  • A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. 
  • A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. 
  • A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. 
  • A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. 
  • A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. 
  • A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. 
  • A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. 
  • A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. 
  • A pial window model for the intracranial study of human glioma microvascular function. 
  • A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. 
  • A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups. 
  • A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. 
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. 
  • A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. 
  • A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line. 
  • A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma. 
  • AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. 
  • ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. 
  • AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization. 
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. 
  • Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. 
  • Acidic stress promotes a glioma stem cell phenotype. 
  • Acute leukemia following treatment of malignant glioma. 
  • Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. 
  • Adherens junctional associated protein-1: a novel 1p36 tumor suppressor candidate in gliomas (Review). 
  • Adoptive immunotherapy for malignant glioma. 
  • Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. 
  • Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model. 
  • Alterations of the TP53 gene in human gliomas. 
  • Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro. 
  • Altered genetic response to beta-adrenergic receptor activation in late passage C6 glioma cells. 
  • Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • An improved method of preparing Schmidt-Ruppin Rous sarcoma virus for brain tumor induction in mammals. 
  • Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. 
  • Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line. 
  • Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. 
  • Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. 
  • Antibody-based immunotherapy for malignant glioma. 
  • Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. 
  • Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. 
  • Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. 
  • Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. 
  • Assessment of type of allergy and antihistamine use in the development of glioma. 
  • Association and interactions between DNA repair gene polymorphisms and adult glioma. 
  • Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. 
  • Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a Chinese population. 
  • Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements. 
  • Avastin: more questions than answers. . . 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Binding of tenascin-C to soluble fibronectin and matrix fibrils. 
  • Biochemical and structural studies of tenascin/hexabrachion proteins. 
  • Biology of gliomas: potential clinical implications of glioma cellular heterogeneity. 
  • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. 
  • Brain cancer stem cells display preferential sensitivity to Akt inhibition. 
  • Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats. 
  • Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations. 
  • Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation. 
  • Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. 
  • Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. 
  • CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. 
  • Cancer immunoediting in malignant glioma. 
  • Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. 
  • Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response. 
  • Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. 
  • Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. 
  • Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. 
  • Cerebral blood flow, blood volume, and vascular permeability of cerebral glioma assessed with dynamic CT perfusion imaging. 
  • Cerebral magnetic resonance: comparison of high and low field strength imaging. 
  • Cerebral physiology in dogs after brain-tumor induction with Schmidt-Ruppin Rous sarcoma virus: experiences with radioiodinated normal and antiviral immunoglobulin G. 
  • Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI. 
  • Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. 
  • Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. 
  • Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. 
  • Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG. 
  • Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas. 
  • Chemotherapy and novel therapeutic approaches in malignant glioma. 
  • Chemotherapy for adults with malignant glioma. 
  • Chemotherapy is useful in the treatment of gliomas. Discussant. 
  • Chemotherapy of brain tumors. 
  • Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Chordoid glioma: a case report and molecular characterization of five cases. 
  • Chromosomal composition of four permanent cultured cell lines derived from human gliomas. 
  • Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. 
  • Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro. 
  • Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. 
  • Clinical immunotherapy for brain tumors. 
  • Clinical trial end points for high-grade glioma: the evolving landscape. 
  • Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. 
  • Combating immunosuppression in glioma. 
  • Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. 
  • Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. 
  • Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. 
  • Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. 
  • Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. 
  • Comparative permeability of different glioma models to horseradish peroxidase. 
  • Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. 
  • Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. 
  • Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. 
  • Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. 
  • Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. 
  • Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 
  • Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats. 
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. 
  • Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. 
  • Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. 
  • Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. 
  • Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors. 
  • Cortical localization of temporal lobe language sites in patients with gliomas. 
  • Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. 
  • Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Current available therapies and future directions in the treatment of malignant gliomas. 
  • Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. 
  • Cytopathologic characteristics of permanent cell lines derived from anaplastic human gliomas. 
  • Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. 
  • DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas. 
  • DNA methyltransferase levels and altered CpG methylation in the total genome and in the GSTP1 gene in human glioma cells transfected with sense and antisense DNA methyltransferase cDNA. 
  • Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. 
  • Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. 
  • Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells. 
  • Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. 
  • Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. 
  • Detecting treatment-by-centre interaction in multi-centre clinical trials. 
  • Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. 
  • Development of novel targeted therapies in the treatment of malignant glioma. 
  • Developmental anomalies of the skin. 
  • Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines. 
  • Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. 
  • Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. 
  • Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. 
  • Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth. 
  • Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. 
  • Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. 
  • Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 
  • Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. 
  • Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. 
  • Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. 
  • Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. 
  • Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. 
  • Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. 
  • Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. 
  • Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma. 
  • EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. 
  • Editorial: Turning fluorescence into black and white. 
  • Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. 
  • Effect of glutamate analogues on brain tumor cell lines. 
  • Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas. 
  • Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. 
  • Effects of therapy on the 1H NMR spectrum of a human glioma line. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. 
  • Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. 
  • Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. 
  • Enhanced oncolytic virotherapy through oxidative stress inhibition. 
  • Enhanced optical imaging of human gliomas and tumor margins. 
  • Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. 
  • Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. 
  • Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. 
  • Epidermal growth factor receptor and variant III targeted immunotherapy. 
  • Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. 
  • Evaluating glioma therapies: modeling treatments and predicting outcomes. 
  • Evaluating radiation-induced white matter changes in patients treated with stereotactic radiosurgery using diffusion tensor imaging: a pilot study. 
  • Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. 
  • Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model. 
  • Evans blue nanocarriers visually demarcate margins of invasive gliomas. 
  • Evidence-based Treatment for Low-grade Glioma. 
  • Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. 
  • Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. 
  • Experience with irinotecan for the treatment of malignant glioma. 
  • Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors. 
  • Experimental gliomas: an autoradiographic study of the endothelial component. 
  • Exploiting metabolic differences in glioma therapy. 
  • Exploring the association between melanoma and glioma risks. 
  • Expression and regulation of calcium-independent protein kinase C in NG 108-15 cell differentiation. 
  • Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. 
  • Factors influencing the cell type of brain tumors induced in dogs by Schmidt-Ruppin Rous sarcoma virus. 
  • Familial gliomas: cases in two pairs of brothers. 
  • Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. 
  • Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. 
  • Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. 
  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. 
  • GD3 expression by cultured human tumor cells of neuroectodermal origin. 
  • GLIOGENE an International Consortium to Understand Familial Glioma. 
  • GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. 
  • Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination. 
  • Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. 
  • Gamma-radiation sensitivity and risk of glioma. 
  • Gamma-ray mutagen sensitivity and survival in patients with glioma. 
  • Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats. 
  • Gene amplification in malignant human gliomas: clinical and histopathologic aspects. 
  • General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors. 
  • Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. 
  • Genetic alterations in glioma and medulloblastoma. 
  • Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. 
  • Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. 
  • Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. 
  • Genetic variations in the homologous recombination repair pathway genes modify risk of glioma. 
  • Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. 
  • Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. 
  • Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. 
  • Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. 
  • Germline mutations in shelterin complex genes are associated with familial glioma. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Glial fibrillary acidic protein synthesized in vitro using messenger RNA from a human glioma cell line. 
  • Glial-mesenchymal tropism of in vivo avian sarcoma virus neuro-oncogenesis in rats. 
  • Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. 
  • Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. 
  • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. 
  • Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. 
  • Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. 
  • Gliomas. 
  • Gliomatosis cerebri presenting with optic nerve involvement: MRI. 
  • Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. 
  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma. 
  • Granular presence of terminin is the marker to distinguish between the senescent and quiescent states. 
  • Grey matter edema: the marginal zone of autochthonous virally-induced gliomas. 
  • Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. 
  • Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. 
  • Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice. 
  • HIF-miR-215-KDM1B promotes glioma-initiating cell adaptation to hypoxia. 
  • Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma. 
  • Ham56-immunoreactive macrophages in untreated infiltrating gliomas. 
  • Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. 
  • Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. 
  • Hexabrachion proteins in embryonic chicken tissues and human tumors. 
  • Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG. 
  • History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). 
  • How heterogeneous are gliomas? 
  • Human brain tumor xenografts. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Hydroxyurea synchronization increases mitotic yield in human glioma cell lines. 
  • Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. 
  • Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. 
  • IDH1 and IDH2 hotspot mutations are not found in canine glioma. 
  • IDH1 and IDH2 mutations in gliomas. 
  • INTRACRANIAL TUMORS IN INFANCY AND CHILDHOOD. A CLINICAL STUDY OF TWENTY CASES. 
  • Identification of a brain- and reproductive-organs-specific gene responsive to DNA damage and retinoic acid. 
  • Identification of an amplified, highly expressed gene in a human glioma. 
  • Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. 
  • Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. 
  • IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. 
  • Immunobiologic aspects of the brain and human gliomas. A review. 
  • Immunobiology of human gliomas. 
  • Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. 
  • Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. 
  • Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. 
  • Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. 
  • Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. 
  • Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs. 
  • Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems. 
  • Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy approaches for malignant glioma from 2007 to 2009. 
  • Immunotherapy approaches in the treatment of malignant brain tumors. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. 
  • Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. 
  • Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. 
  • In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. 
  • In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. 
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. 
  • In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. 
  • In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line. 
  • In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. 
  • Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. 
  • Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. 
  • Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. 
  • Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. 
  • Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. 
  • Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. 
  • Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. 
  • Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats. 
  • Influence of glutamine on the growth of human glioma and medulloblastoma in culture. 
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. 
  • Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. 
  • Intergeneric poliovirus recombinants for the treatment of malignant glioma. 
  • Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. 
  • Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. 
  • Interstitial hyperthermia and iridium brachytherapy in treatment of malignant glioma. A phase I clinical trial. 
  • Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. 
  • Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. 
  • Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. 
  • Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. 
  • Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. 
  • Intracerebral transplantation of a human glioma line in immunosuppressed rats. 
  • Intraoperative mapping during repeat awake craniotomy reveals the functional plasticity of adult cortex. 
  • Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. 
  • Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. 
  • Introduction. 
  • Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice. 
  • Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. 
  • Iodine-125 interstitial irradiation of virally induced dog brain tumours. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Irinotecan therapy in adults with recurrent or progressive malignant glioma. 
  • Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. 
  • Isocitrate dehydrogenase mutations in gliomas. 
  • Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. 
  • Isolation of Glioma-Initiating Cells for Biological Study. 
  • Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study. 
  • L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. 
  • L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. 
  • Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. 
  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. 
  • Local delivery methods of therapeutic agents in the treatment of diffuse intrinsic brainstem gliomas. 
  • Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. 
  • Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. 
  • Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. 
  • Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. 
  • Loss of heterozygosity for 10q loci in human gliomas. 
  • Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. 
  • MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. 
  • MR measurement of normal and pathologic brainstem diameters. 
  • MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. 
  • Macrophage markers in diagnostic neuropathology. 
  • Magnetic resonance imaging of optic gliomas. 
  • Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. 
  • Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. 
  • Malignant glioma--timing of response to radiation therapy. 
  • Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. 
  • Managing intracranial incidental findings suggestive of low-grade glioma: learning from experience. 
  • Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. 
  • Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. 
  • Maximizing the efficacy of angiogenesis inhibitors. 
  • Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize? 
  • Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. 
  • Mechanisms of action of rapamycin in gliomas. 
  • Medical diagnostic radiation exposures and risk of gliomas. 
  • Medulloblastoma cell-substrate interaction in vitro. 
  • Mendelian randomisation study of the relationship between vitamin D and risk of glioma. 
  • Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. 
  • Met and hepatocyte growth factor/scatter factor expression in human gliomas. 
  • Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. 
  • Microglioma, a histiocytic neoplasm of the central nervous system. 
  • Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. 
  • Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. 
  • Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. 
  • Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. 
  • Molecular pathogenesis of malignant gliomas. 
  • Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. 
  • Molecularly targeted therapy for malignant glioma. 
  • Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. 
  • Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species. 
  • Monoclonal antibodies to malignant human gliomas. 
  • Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. 
  • Monoclonal antibody therapy of human gliomas: current status and future approaches. 
  • Morphologic and molecular genetic aspects of oligodendroglial neoplasms. 
  • Morphologic observations of brain tumors in PD4 hamsters induced by four strains of avian sarcoma virus. 
  • Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. 
  • Mutagen sensitivity and risk of gliomas: a case-control analysis. 
  • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 
  • N-acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. 
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 
  • Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. 
  • Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. 
  • Neuroradiology case of the day. Gliomatosis cerebri. 
  • Non-additive and epistatic effects of HLA polymorphisms contributing to risk of adult glioma. 
  • Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. 
  • Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas 
  • O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. 
  • Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. 
  • Oncogene amplification in pediatric brain tumors. 
  • Oncogenes and anti-oncogenes in human central nervous system tumors. 
  • Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. 
  • PTEN gene mutations are seen in high-grade but not in low-grade gliomas. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia. 
  • Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies. 
  • Patterns of the early, gross chromosomal changes in malignant human gliomas. 
  • Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. 
  • Pediatric high-grade glioma: biologically and clinically in need of new thinking. 
  • Pericytic-like angiotropism of glioma and melanoma cells. 
  • Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. 
  • Permeability of different experimental brain tumor models to horseradish peroxidase. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. 
  • Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. 
  • Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. 
  • Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. 
  • Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. 
  • Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. 
  • Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. 
  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. 
  • Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). 
  • Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. 
  • Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. 
  • Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. 
  • Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. 
  • Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. 
  • Phase II study of carboplatin in children with progressive low-grade gliomas. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phase II trial of temozolomide in patients with progressive low-grade glioma. 
  • Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. 
  • Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. 
  • Plasma osmolality and brain water content in a rat glioma model. 
  • Plasmonics-enhanced and optically modulated delivery of gold nanostars into brain tumor. 
  • Poliovirus receptor CD155-targeted oncolysis of glioma. 
  • Polymorphisms of DNA repair genes and risk of glioma. 
  • Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. 
  • Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. 
  • Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. 
  • Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population. 
  • Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. 
  • Postoperative radiation therapy for low-grade glioma: patterns of care between 1998 and 2006. 
  • Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies. 
  • Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. 
  • Predicting grade of cerebral glioma using vascular-space occupancy MR imaging. 
  • Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. 
  • Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. 
  • Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. 
  • Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. 
  • Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. 
  • Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. 
  • Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. 
  • Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas. 
  • Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. 
  • Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. 
  • Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Proteomic and immunologic analyses of brain tumor exosomes. 
  • Purification of hexabrachion (tenascin) from cell culture conditioned medium, and separation from a cell adhesion factor. 
  • Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. 
  • Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. 
  • Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. 
  • Quantitative proton spectroscopy and histology of a canine brain tumor model. 
  • Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. 
  • Radiation-induced malignant gliomas: a current review. 
  • Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. 
  • Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. 
  • Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. 
  • Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. 
  • Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. 
  • Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. 
  • Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. 
  • Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. 
  • Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. 
  • Rational for "eight-in-one" chemotherapy. 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Recurrent isolated sixth nerve palsy in children. 
  • Recurrent malignant gliomas. 
  • Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. 
  • Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. 
  • Regional measurements of blood flow in experimental RG-2 rat gliomas. 
  • Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. 
  • Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relationship between gene amplification and chromosomal deviations in malignant human gliomas. 
  • Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. 
  • Releasing the block: setting differentiation free with mutant IDH inhibitors. 
  • Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. 
  • Response assessment criteria for brain metastases: proposal from the RANO group. 
  • Response to "the epidemiology of glioma in adults: a 'state of the science' review". 
  • Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. 
  • Risk assessment for developing gliomas: a comparison of two cytogenetic approaches. 
  • Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. 
  • SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. 
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. 
  • Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. 
  • Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. 
  • Second messenger systems in human gliomas. 
  • Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. 
  • Selection bias, survival, and brachytherapy for glioma. 
  • Selection of a management strategy for pediatric brainstem tumors. 
  • Selective modification of antigen-specific T cells by RNA electroporation. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. 
  • Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population. 
  • Single-photon-emission computed tomographic imaging of glioma. 
  • Sodium and water regulation in a patient with cerebral salt wasting. 
  • Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. 
  • Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. 
  • Some structural aspects of dog brain tumors induced with the Schmidt-Ruppin strain of the Rous sarcoma virus. 
  • Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas. 
  • Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. 
  • Specific chromosomal abnormalities in malignant human gliomas. 
  • Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). 
  • Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. 
  • Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. 
  • Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. 
  • Structural alterations of the epidermal growth factor receptor gene in human gliomas. 
  • Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor. 
  • Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. 
  • Surface antigenic characteristics of human glial brain tumor cells. 
  • Surface antigens of human glioma cells shared with normal adult and fetal brain. 
  • Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. 
  • Survival and low-grade glioma: the emergence of genetic information. 
  • Susceptibility of inbred Fischer rats to brain tumor induction by Rous sarcoma virus. 
  • Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model. 
  • Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. 
  • Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. 
  • Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • T2 estimates in healthy and diseased brain tissue: a comparison using various MR pulse sequences. 
  • TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. 
  • TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 
  • Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. 
  • Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. 
  • Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. 
  • Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. 
  • Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. 
  • Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. 
  • Targeting cancer stem cells through L1CAM suppresses glioma growth. 
  • Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. 
  • Telomere length connects melanoma and glioma predispositions. 
  • Telomere maintenance and the etiology of adult glioma. 
  • Temozolomide and treatment of malignant glioma. 
  • Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. 
  • Temozolomide in children with progressive low-grade glioma. 
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. 
  • Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. 
  • Tenascin expression in human glioma cell lines and normal tissues. 
  • The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. 
  • The Effects of Thermal Preconditioning on Oncogenic and Intraspinal Cord Growth Features of Human Glioma Cells. 
  • The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. 
  • The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. 
  • The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. 
  • The biology of malignant gliomas--a comprehensive survey. 
  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. 
  • The dependence of nuclear magnetic resonance (NMR) image contrast on intrinsic and pulse sequence timing parameters. 
  • The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. 
  • The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. 
  • The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. 
  • The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. 
  • The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. 
  • The emerging role of anti-angiogenic therapy for malignant glioma. 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The epidemiology of glioma in adults: a "state of the science" review. 
  • The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus. 
  • The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. 
  • The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. 
  • The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. 
  • The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. 
  • The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3':5'-cyclic monophosphate. 
  • The paradoxical effect of bevacizumab in the therapy of malignant gliomas. 
  • The paradoxical effect of bevacizumab in the therapy of malignant gliomas. 
  • The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. 
  • The role of the subependymal plate in glial tumorigenesis. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • The use of motor mapping to aid resection of eloquent gliomas. 
  • Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. 
  • Therapeutic analysis of in vitro and in vivo brain tumor models. 
  • Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. 
  • Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. 
  • Therapeutic profile of the human glioma line D-54 MG in athymic mice. 
  • There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. 
  • Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. 
  • Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. 
  • Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. 
  • Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. 
  • Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials. 
  • Treatment of Gliomas: A Changing Landscape. 
  • Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids. 
  • Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report. 
  • Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. 
  • Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin. 
  • Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. 
  • Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. 
  • Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. 
  • Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. 
  • Treatment of patients with recurrent primary brain tumors with AZQ. 
  • Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. 
  • Tumor hypoxia and prognosis in human gliomas. 
  • Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. 
  • Tumor progression and transformation of low-grade glial tumors associated with pregnancy. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. 
  • Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Vaccine Therapy, Oncolytic Viruses, and Gliomas. 
  • Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. 
  • Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. 
  • Vascular-targeted photothermal therapy of an orthotopic murine glioma model. 
  • Virus-cell relationships in dog brain tumors induced with Schmidt-Ruppin Rous sarcoma virus. 
  • Viruses and oncogenes in brain tumors. 
  • Viruses as therapeutic agents against malignant disease of the central nervous system. 
  • Viruses for the treatment of malignant glioma. 
  • Viruses in the treatment of brain tumors. 
  • Viruses in the treatment of malignant glioma. 
  • ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. 
  • [Benzodiazepine receptors of the mouse glioblastoma cell line: the anomalous effect of gamma-aminobutyric acid on diazepam binding]. 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
  • [New type of specific binding sites for gamma-aminobutyric acid (GABA) found in a mouse glioblastoma]. 
  • [Oncolytic viral therapy of gliomas: review of the literature] 
  • c-Myc is required for maintenance of glioma cancer stem cells. 
  • cAMP stimulates transcription of the beta 2-adrenergic receptor gene in response to short-term agonist exposure. 
  • miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. 
• 

  Keywords of People

  • Affronti, Mary Louise, Associate Professor in the School of Nursing, School of Nursing
  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • Diplas, Bill, Student, Pathology
  • Hoang, Jenny K., Associate Professor of Radiology, Radiology, Neuroradiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology